Evidence map›Paper›PMID 40665093›Full record

ArticleAnnals of nuclear medicine2025

Comparison of diagnostic performance between manual diagnosis following PROMISE V2 and aPROMISE utilizing Ga/F-PSMA PET/CT.

Yuki Enei, Takafumi Yanagisawa, Atsuya Okada, Hidetoshi Kuruma, Chieko Okazaki, Ken Watanabe, Nat P Lenzo, Takahiro Kimura, Kenta Miki

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. PSMA-Targeted radiopharmaceuticals: from diagnosis to risk & quality of life.European journal of nuclear medicine and molecular imaging · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuki Enei *Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan.ORCID http://orcid.org/0009-0006-1124-2322
Takafumi Yanagisawa *Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan. t.yanagisawa.jikei@gmail.com.
Atsuya OkadaJinsenkai MI Clinic, Osaka, Japan.
Hidetoshi KurumaBashamichi Sakura Clinic, Yokohama, Japan.
Chieko OkazakiTheranostics Yokohama, Yokohama, Japan.
Ken WatanabeDepartment of Radiology, The Jikei University School of Medicine, Minato-Ku, Tokyo, Japan.
Nat P LenzoICON Cancer Centre, Midland, WA, Australia.
Takahiro KimuraDepartment of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan.
Kenta MikiDepartment of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundsAutomated PROMISE (aPROMISE), which is an artificial intelligence-supported software for prostate-specific membrane antigen (PSMA) PET/CT based on PROMISE V2, has demonstrated diagnostic utility with better correspondence rates compared to manual diagnosis. However, previous studies have consistently utilized MATERIALS AND

methodsWe retrospectively evaluated 21 PSMA PET/CT images (

resultsaPROMISE-assisted diagnosis was significantly associated with shorter median diagnostic time compared to manual diagnosis (427 s [IQR: 370-834] vs. 1,114 s [IQR: 922-1291], p < 0.001). The time reduction with aPROMISE-assisted diagnosis was particularly notable when using

conclusionsDespite the preliminary nature of the study, aPROMISE-assisted diagnosis significantly reduces diagnostic time and achieves satisfactory accuracy compared to manual diagnosis. While aPROMISE is effective in detecting bone metastases, its limitations in identifying lymph node and visceral metastases must be carefully addressed. This study supports the utility of aPROMISE in Japanese patients with mPCa and underscores the need for further validation in larger cohorts.

Indexed as

Edetic AcidImage Processing, Computer-AssistedPositron Emission Tomography Computed TomographyProstatic NeoplasmsSoftwareAgedAged, 80 and overAutomationFluorine RadioisotopesGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedNeoplasm MetastasisRetrospective StudiesEdetic AcidFluorine Radioisotopesgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesAPROMISEArtificial intelligenceDiagnosisMetastatic prostate cancerPROMISE V2PSMA PET/CT

Identifiers

PMID40665093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.